Acelrx reports third quarter 2023 financial results and provides corporate update

Niyad™ investigational device exemption (ide) approval by the fda achieved in third quarter company plans to begin its niyad registrational study this quarter with topline data expected mid-2024 cash and investments of $13.4 million as of september 30, 2023 financing closed in july led by new healthcare investors providing up to $26.3 million, of which $10 million was made immediately available key opinion leader panel discussion on niyad planned for december 6 th webcast and conference call to be held today at 4:30 p.m. et san mateo, calif.
ACRX Ratings Summary
ACRX Quant Ranking